Status:
COMPLETED
Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Conditions:
COVID-19
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and cri...
Eligibility Criteria
Inclusion
- confirmed COVID-19 disease
- refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg
- IL6 ≥ 500 ng/l
- Indication for CRRT or ECMO
Exclusion
- Liver cirrhosis Child Pugh C
- "do not resuscitate"-order
- expected survival due to comorbidities \< 14 days
- pregnancy or breastfeeding
- participation in another interventional trial
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04344080
Start Date
April 1 2020
End Date
April 28 2021
Last Update
September 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Hamburg-Eppendorf
Hamburg, Germany